• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by STAAR Surgical Company

    6/21/24 4:46:18 PM ET
    $STAA
    Ophthalmic Goods
    Health Care
    Get the next $STAA alert in real time by email
    S-8 1 2024_form_s-8_equity_pla.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on June 21, 2024

    Registration No. 333-_____

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ___________________________________________________________

    Form S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    STAAR Surgical Company

    (Exact Name of Registrant as Specified in Charter)

     

     

    Delaware
    (State or other jurisdiction of
    incorporation or organization

    95‑3797439
    (I.R.S. Employer
    Identification No.)

     

    25651 Atlantic Ocean Drive

    Lake Forest, California 92630

    (Address of Principal Executive Offices) (Zip Code)

    ___________________________________________________________

    STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan

    (Full title of the plan)

    ___________________________________________________________

    Nathaniel B. Sisitsky, Esq.

    General Counsel and Corporate Secretary

    STAAR Surgical Company

    25651 Atlantic Ocean Drive

    Lake Forest, California 92630

    (Name and address of agent for service)

    (626) 303-7902

    (Telephone number, including area code, of agent for service)

    ___________________________________________________________

    COPY TO:

    Lori Zyskowski, Esq.

    Gibson, Dunn & Crutcher LLP

    200 Park Avenue, New York, NY 10166-0193

    ___________________________________________________________

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and emerging growth company in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☑

    Accelerated filer ☐

    Non-accelerated filer ☐

    Smaller reporting company ☐

     

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) of STAAR Surgical Company (the “Company”) registers an aggregate of 4,770,000 shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), for issuance under the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan, as amended (the “Plan”) comprised of (i) an increase of 2,170,000 shares of Common Stock reserved for issuance under the Plan pursuant to an amendment and restatement of the Plan approved by the Company’s shareholders at the Company's 2023 Annual Meeting of Shareholders held on June 15, 2023, and (ii) an increase of 2,600,000 shares of Common Stock reserved for issuance under the Plan pursuant to an amendment to the Plan approved by the Company's shareholders at the Company's 2024 Annual Meeting of Shareholders held on June 20, 2024. Following such share increases, the aggregate number of shares of Common Stock that may be issued under the Plan is 22,805,000.

     

     

     

     

     


     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants in the Plan, as required by Rule 428(b)(1) promulgated by the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Securities Act Rule 424 in accordance with the Note to Part I of Form S-8. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

    I - 1


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Company incorporates by reference in this Registration Statement the documents listed below, excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):

    •
    the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2023, filed with the Commission on February 27, 2024;
    •
    the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2024, filed with the Commission on May 7, 2024;
    •
    the Company’s Current Reports on Form 8-K filed with the Commission on March 12, 2024, and June 21, 2024; and
    •
    the description of the Company's Common Stock contained in Amendment No. 1 to the Company's Registration Statement on Form 8-A/A filed with the Commission on April 18, 2003, including any amendment or report filed for the purpose of updating this description.

    In addition, all documents subsequently filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents (excluding any documents or portions of documents that have been “furnished” but not “filed” for purposes of the Exchange Act).

     

    Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement will be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law (the “DGCL”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement in connection with specified actions, suits or proceedings, whether civil, criminal, administrative or investigative (other than a “derivative action” — an action by or in the right of the corporation) if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceedings, had no reasonable cause to believe their conduct was unlawful.

    A similar standard applies in the case of derivative actions, except that indemnification only extends to expenses (including attorneys’ fees) actually and reasonably incurred in connection with the defense or settlement of a derivative action, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation’s certificate of incorporation, by-laws, disinterested director vote, stockholder vote, agreement or otherwise.

    II - 1


     

    As permitted by Section 145 of the DGCL, Article 6 of the Company’s certificate of incorporation, as amended, provides:

    “The Corporation shall to the full extent permitted by Section 145 of the DGCL have the power to indemnify all persons whom it may indemnify pursuant thereto.”

    The Company’s by-laws provide for indemnification of officers and directors to the fullest extent permitted by Delaware law. In addition, the Company has, and intends in the future to enter into, agreements to provide indemnification for directors and officers in addition to that provided for in the by-laws.

    The Company maintains an insurance policy pursuant to which its directors and officers are insured, within the limits and subject to the limitations of the policy, against specified expenses in connection with the defense of claims, actions, suits or proceedings, and liabilities which might be imposed as a result of such claims, actions, suits or proceedings, that may be brought against them by reason of their being or having been directors or officers.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following documents are filed as exhibits to this Registration Statement.

     

    Exhibit Number

     

    Description of Exhibit

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix 2 to the Company's Proxy Statement on Form DEF 14A as filed with the Commission on April 26, 2018).

    4.2

     

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the Commission on February 1, 2023).

    5.1*

     

    Opinion of Gibson, Dunn & Crutcher LLP.

    23.1*

     

    Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).

    23.2*

     

    Consent of BDO USA, P.C.

    24.1*

     

    Power of Attorney (included in the signature page to this Registration Statement).

    99.1

     

    STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on June 21, 2024).

    99.2

     

    Amendment No. 1 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the Commission on June 21, 2024).

    107.1*

     

    Filing Fee Table.

    ________

    * Filed herewith.

    Item 9. Undertakings.

    (a) The undersigned registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement; and

    II - 2


     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or 15(d) of the Exchange Act, that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II - 3


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lake Forest, State of California, on June 21, 2024.

    STAAR SURGICAL COMPANY

    By:

    /s/ Tom Frinzi

    Thomas G. Frinzi

     

     

    President, Chief Executive Officer and Chair of the Board

    (principal executive officer)

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each of the undersigned directors and officers of STAAR Surgical Company, a Delaware corporation (the “Company”), hereby nominate and appoint Thomas G. Frinzi, Nathaniel B. Sisitsky and Patrick F. Williams and each of them acting or signing singly, as his or her agents and attorneys-in-fact (the “Agents”), for the undersigned and in the undersigned’s name, place and stead, in any and all capacities, to sign a Registration Statement on Form S-8 under the Securities Act of 1933, as amended, (the “Securities Act”), in connection with the registration under the Securities Act of shares of the Company’s common stock issuable under the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan, as amended, and any and all amendments (including post-effective amendments) to such Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto the Agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully cause to be done by virtue hereof.

    This Power of Attorney shall remain in full force and effect until revoked or superseded by written notice filed with the Securities and Exchange Commission.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

    /s/ Tom Frinzi

    President, Chief Executive Officer and Chair of the Board, Director

    June 21, 2024

    Thomas G. Frinzi

    (Principal Executive Officer)

    /s/ Patrick F. Williams

    Chief Financial Officer

    June 21, 2024

    Patrick F. Williams

    (Principal Financial and Accounting Officer)

    /s/ Arthur C. Butcher

    Director

    June 21, 2024

    Arthur C. Butcher

    /s/ Stephen C. Farrell

    Director

    June 21, 2024

    Stephen C. Farrell

    /s/ Wei Jiang

    Director

    June 21, 2024

    Wei Jiang

    /s/ Aimee Weisner

    Director

    June 21, 2024

    Aimee Weisner

    /s/ Elizabeth Yeu

    Director

    June 21, 2024

    Elizabeth Yeu

    /s/ Lilian Zhou

    Director

    June 21, 2024

    Lilian Zhou

     

    II - 4


    Get the next $STAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STAA

    DatePrice TargetRatingAnalyst
    2/3/2026$26.00Neutral
    Wedbush
    1/16/2026$13.00Underweight
    Morgan Stanley
    4/21/2025$17.00Equal Weight
    Wells Fargo
    2/12/2025Buy → Hold
    Jefferies
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    2/12/2025Buy → Neutral
    BTIG Research
    2/12/2025Outperform → Mkt Perform
    William Blair
    7/15/2024$50.00 → $37.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

    Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.

    2/2/26 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

    Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%

    1/15/26 8:30:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Terminates Agreement to Acquire STAAR Surgical

    Ad hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) announced on August 5, 2025. "Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight® plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantiv

    1/6/26 8:00:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on STAAR Surgical with a new price target

    Wedbush initiated coverage of STAAR Surgical with a rating of Neutral and set a new price target of $26.00

    2/3/26 8:08:13 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Morgan Stanley resumed coverage on STAAR Surgical with a new price target

    Morgan Stanley resumed coverage of STAAR Surgical with a rating of Underweight and set a new price target of $13.00

    1/16/26 8:34:38 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Wells Fargo initiated coverage on STAAR Surgical with a new price target

    Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00

    4/21/25 8:38:55 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    SEC Filings

    View All

    STAAR Surgical Company filed SEC Form 8-K: Leadership Update

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    2/5/26 8:06:41 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    2/2/26 7:00:26 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Company filed SEC Form 8-K: Leadership Update

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    1/16/26 8:30:25 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Christopher Min Fang claimed ownership of 3,257,130 shares (SEC Form 3)

    3 - STAAR SURGICAL CO (0000718937) (Issuer)

    2/10/26 7:43:52 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Interim Co-CEO and Pres. & COO Foust Warren

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    2/4/26 5:29:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    2/4/26 5:28:24 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $606,138 worth of shares (27,485 units at $22.05) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/13/26 9:30:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $8,817,664 worth of shares (406,653 units at $21.68) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    1/8/26 7:31:31 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $41,060,317 worth of shares (1,500,000 units at $27.37) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    11/21/25 9:55:23 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Financials

    Live finance-specific insights

    View All

    STAAR Surgical Reports Third Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025. Third Quarter 2025 Financial Overview Net sales of $94.7 million up 6.9% Y/Y Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the "December China Shipment") Net sales excluding China of $38.9 million up 7.7% Y/Y Gross margin at 82.2% vs. 77.3% year ago due to the timing of the reco

    11/5/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Second Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

    8/6/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

    Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.

    2/2/26 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

    Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%

    1/15/26 8:30:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    1/26/24 9:19:42 AM ET
    $STAA
    Ophthalmic Goods
    Health Care